Last updated: 2026-10-17 20:22:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Stoke Therapeutics, Inc. (STOK) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $24.19, with a market capitalization of $1.59B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $20.32 to $40.22. This page covers its latest market performance, valuation, price trends and company information.
$1.59B | |
$24.56 | |
$71.58 | |
$3.35 | |
$24.61 | |
592.79K | |
882.00K | |
-- | |
$40.22 | |
$20.32 | |
-- | |
-- |
Stoke Therapeutics, Inc. (STOK) last closed at $24.61 as of 2026-10-16 23:57:00, unchanged from the previous close of $24.61.
During the latest regular trading session, STOK traded between $3.35 and $71.58, with a volume of 592.79K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Stoke Therapeutics, Inc. (STOK) moved from $23.95 to $24.19, representing a gain of 0.99% ($0.24).
The stock traded between $22.05 and $26.67 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 770.05 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 19.4%
STOK is currently trading at $24.19, placing it 19.4% of the way from its 52-week low of $20.32 to its 52-week high of $40.22. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 170 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Stoke Therapeutics, Inc. (STOK) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.